JAGUAR HEALTH, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M |
| Cost of Revenue | $3.8M | $2.0M | $2.0M | $2.0M | $2.3M | $3.3M | $3.8M | $2.8M |
| Gross Profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M |
| Gross Margin | 67.2% | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% | 33.9% | 37.4% |
| Operating Expenses | ||||||||
| Research & Development | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M |
| SG&A Expense | $18.6M | $16.3M | $16.6M | $17.9M | $17.1M | $14.4M | $13.5M | $12.3M |
| Operating Income | $-45.9M | $-30.8M | $-34.3M | $-34.4M | $-40.7M | $-26.6M | $-28.9M | $-30.8M |
| Operating Margin | -398.8% | -263.8% | -351.3% | -287.8% | -939.1% | -283.9% | -501.3% | -698.0% |
| Interest Expense | $67.0K | $231.0K | $6.4M | $12.7M | $8.4M | $2.8M | $5.7M | $2.6M |
| Pretax Income | $-54.0M | $-39.3M | $-41.9M | $-48.4M | $-52.6M | $-33.8M | $-38.5M | $-32.1M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $10.0K | — |
| Net Income | $-53.6M | $-38.5M | $-41.9K | $-48.4K | $-52.6K | $-33.8M | $-38.5M | $-32.1M |
| Net Margin | -465.4% | -329.3% | -0.4% | -0.4% | -1.2% | -360.2% | -667.3% | -727.9% |
| EPS (Basic) | $-22.97 | $-16.34 | $-334.77 | $-0.25 | $-0.31 | $-0.01 | $-0.03 | $-0.53 |
| EPS (Diluted) | $-22.97 | $-16.34 | $-334.77 | $-0.25 | $-0.31 | $-0.01 | $-0.03 | $-0.53 |
| Shares Outstanding (Basic) | 2.3M | 2.4M | 184.5M | 188.9M | 171.7M | 3.71B | — | 48.48B |
| Shares Outstanding (Diluted) | 2.3M | 2.4M | 184.5M | 188.9M | 171.7M | 3.71B | — | 48.48B |
| Dividends Per Share | — | — | — | — | — | — | — | — |